使用依达赛珠单抗逆转达比加群以促进急性卒中溶栓后的不良临床结局。 - Suppr | 超能文献

相似文献

1

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.使用依达赛珠单抗逆转达比加群以促进急性卒中溶栓后的不良临床结局。

J Neurol. 2017 Mar;264(3):591-594. doi: 10.1007/s00415-017-8410-6. Epub 2017 Feb 6.

2

Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation.依达赛珠单抗辅助静脉溶栓治疗急性卒中伴达比加群：两例发生出血性转化的病例

J Neurol Sci. 2018 May 15;388:155-157. doi: 10.1016/j.jns.2018.03.021. Epub 2018 Mar 14.

3

Acute stroke thrombolysis following dabigatran reversal using idarucizumab.使用艾达司珠单抗逆转达比加群后进行急性卒中溶栓治疗。

Neurol India. 2019 Mar-Apr;67(2):568-570. doi: 10.4103/0028-3886.258032.

4

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.使用依达赛珠单抗逆转达比加群抗凝后成功进行缺血性卒中的静脉溶栓治疗：一例报告

J Med Case Rep. 2017 Aug 15;11(1):224. doi: 10.1186/s13256-017-1404-2.

5

Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.达比加群用依达赛珠单抗逆转后在严重心源性栓塞性卒中中的溶栓治疗：病例报告及文献综述

J Stroke Cerebrovasc Dis. 2018 Jul;27(7):e128-e131. doi: 10.1016/j.jstrokecerebrovasdis.2018.02.025. Epub 2018 Mar 16.

6

Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.使用依达赛珠单抗急性逆转达比加群以进行静脉溶栓作为急性卒中治疗

J Clin Neurosci. 2019 Jan;59:355-357. doi: 10.1016/j.jocn.2018.09.027. Epub 2018 Oct 9.

7

Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.使用依达赛珠单抗逆转达比加群酯后急性缺血性卒中的全身溶栓治疗——病例报告

J Stroke Cerebrovasc Dis. 2017 Jul;26(7):e123-e125. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.039. Epub 2017 May 4.

8

Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab.达比加群酯用艾达司珠单抗逆转后急性缺血性卒中成功溶栓治疗。

BMJ Case Rep. 2019 May 5;12(5):e229128. doi: 10.1136/bcr-2018-229128.

9

Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.达比加群抗凝治疗期间发生急性卒中，采用艾达赛珠单抗和静脉注射组织型纤溶酶原激活剂治疗。

J Stroke Cerebrovasc Dis. 2017 Jun;26(6):e102-e104. doi: 10.1016/j.jstrokecerebrovasdis.2016.12.037. Epub 2017 Apr 14.

10

Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?急性卒中患者应用艾达司珠单抗后静脉溶栓——血栓对溶栓的敏感性是否可能增加？

J Stroke Cerebrovasc Dis. 2019 Mar;28(3):768-773. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.019. Epub 2018 Dec 6.

引用本文的文献

1

Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke.达比加群酯抗凝逆转剂依达鲁单抗用于缺血性和出血性脑卒中的标准操作流程。

J Thromb Thrombolysis. 2023 Apr;55(3):506-518. doi: 10.1007/s11239-023-02772-3. Epub 2023 Feb 4.

2

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.依达赛珠单抗逆转达比加群后的静脉溶栓治疗：文献系统评价

Front Neurol. 2021 Jun 3;12:666086. doi: 10.3389/fneur.2021.666086. eCollection 2021.

3

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.

本文引用的文献

1

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.依达赛珠单抗没有促凝血作用：健康志愿者中血栓形成生物标志物的评估。

Thromb Haemost. 2017 Jan 26;117(2):269-276. doi: 10.1160/TH16-05-0385. Epub 2016 Dec 1.

2

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.达比加群经艾达西珠单抗逆转后用于急性缺血性卒中的静脉溶栓治疗——一例报告

Ann Clin Transl Neurol. 2016 Sep 17;3(11):889-892. doi: 10.1002/acn3.346. eCollection 2016 Nov.

3

Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.